Are GLP-1 medications FDA-approved for addiction treatment?

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved for type 2 diabetes and obesity management. Their use in addiction treatment is currently off-label, meaning it is based on emerging clinical evidence rather than a formal FDA indication. Carrara's medical team prescribes GLP-1 medications as part of a comprehensive, individualized treatment plan when clinically appropriate.

Which addictions can GLP-1 medications help treat?

Current clinical research supports the use of GLP-1 medications in reducing cravings and consumption for alcohol, opioids, nicotine, and stimulants including cocaine and methamphetamine. The mechanism involves modulation of dopamine reward pathways in the brain, reducing the reinforcing effects of addictive substances.

How does Carrara integrate GLP-1 therapy into treatment?

Carrara uses a four-stage protocol: (1) Medical Stabilization — safe initiation of GLP-1 therapy with withdrawal management; (2) Metabolic Repair — addressing nutritional deficiencies and metabolic dysfunction common in substance use disorder; (3) Neurological Regeneration — combining GLP-1 therapy with trauma-informed psychotherapy, neurofeedback, and somatic work; (4) Longevity Planning — developing a post-discharge medication management and lifestyle protocol.

Is GLP-1 therapy a standalone treatment for addiction?

No. GLP-1 medication is never the program on its own. At Carrara, it is one component of a comprehensive treatment model that addresses the neurochemical, emotional, relational, and spiritual dimensions of recovery. Medication reduces the biological pull of cravings; the broader Carrara program addresses the underlying causes of addiction.

What does GLP-1 addiction treatment cost at Carrara?

Carrara is an ultra-luxury residential treatment facility and pricing reflects the level of individualized medical care, staffing, and amenities provided. For a confidential admissions conversation and to discuss your specific situation, please call (888) 383-5207. Our team is available 24 hours a day, 7 days a week.

Carrara Treatment / Integrative Medicine

GLP-1 Medications for Addiction Treatment

What the Research Shows and How Carrara Is Leading

Medically Reviewed by Dr. Kenneth Spielvogel, MD, Senior Medical Officer

Home / Services / GLP-1 Addiction Treatment

Patients taking GLP-1 receptor agonists for diabetes and obesity have been reporting something their doctors did not expect: a significant, sometimes dramatic, reduction in cravings for alcohol, nicotine, opioids, and other substances. What began as anecdotal observation is now supported by a rapidly growing body of clinical research — and it may represent one of the most meaningful advances in addiction pharmacology in decades.

At Carrara Treatment Wellness & Spa, we are not waiting for the science to catch up to our clients’ needs. Under the direction of our medical team, we have integrated GLP-1 therapy into our personalized, ultra-luxury treatment programs — combining cutting-edge pharmacology with deep clinical work, metabolic restoration, and holistic care.

A pill is never the program. GLP-1 medication addresses addiction at the neurochemical level while the broader Carrara model addresses the emotional, relational, and spiritual dimensions of recovery.

Ready to explore GLP-1 as part of your recovery?

GLP-1 medications may help rewire the brain's reward pathways. Find out if you qualify.

Call (888) 383-5207

What Are GLP-1 Medications?

GLP-1 receptor agonists were originally developed to treat type 2 diabetes and, more recently, obesity. They work by mimicking glucagon-like peptide-1, a naturally occurring hormone that regulates blood sugar, slows digestion, and signals fullness to the brain.

The most well-known GLP-1 medications include:

Semaglutide — brand names Ozempic, Wegovy, Rybelsus
Liraglutide — brand names Victoza, Saxenda
Tirzepatide — brand names Mounjaro, Zepbound
Exenatide — brand name Byetta

What caught the attention of addiction researchers was an unexpected finding: patients taking these medications for diabetes or weight loss began reporting that their cravings for alcohol, nicotine, and other substances had dramatically decreased — sometimes disappearing entirely.

The Science: How GLP-1 Medications Work on Addiction

The Dopamine Connection

Addiction is fundamentally a disorder of the brain’s reward circuitry. Substances like alcohol, opioids, and cocaine flood the brain with dopamine — the neurotransmitter associated with pleasure and motivation. Over time, the brain adapts. It takes more of the substance to feel the same effect, natural pleasures feel muted, and the compulsive drive to use intensifies.

GLP-1 receptors are expressed throughout addiction-relevant brain regions, including the ventral tegmental area (VTA), the nucleus accumbens, and the prefrontal cortex. When GLP-1 medications activate these receptors, they modulate dopamine signaling — dampening the exaggerated reward response that drives compulsive substance use without eliminating the capacity for natural pleasure.

GLP-1 medications turn down the volume on cravings. They don’t make someone feel numb or flat. They restore a more balanced relationship with reward and motivation.

Beyond Dopamine: Multiple Pathways

The mechanism is more sophisticated than dopamine modulation alone. Research shows that GLP-1 medications affect reward processing through multiple pathways:

Gut-brain vagal signaling that influences appetite and craving at a visceral level
Neuroinflammatory modulation that reduces brain inflammation associated with chronic substance use
Glutamatergic and GABAergic neurotransmission regulation in reward circuits
Neuroendocrine and affective circuit recalibration during withdrawal

This multi-pathway effect helps explain why GLP-1 medications appear to reduce cravings across different types of addiction — not just alcohol, but opioids, stimulants, nicotine, and even compulsive behaviors.

What the Research Shows

Alcohol Use Disorder

A landmark 2025 randomized clinical trial published in JAMA Psychiatry found that adults with alcohol use disorder who received semaglutide for nine weeks reported significantly lower alcohol cravings and consumed fewer drinks on the days they did drink, compared with the placebo group.

Separately, a large-scale study published in Nature Communications analyzed electronic health records of over 83,000 patients and found that those prescribed semaglutide had a 50% to 56% lower risk of developing or relapsing into alcohol use disorder compared with those taking other anti-obesity medications.

Opioid Use Disorder

One significant study showed that GLP-1 medication reduced opioid cravings by 40% over just three weeks. Preclinical research has demonstrated that GLP-1 receptor activation reduces drug-induced reinstatement of heroin-seeking behavior — a key predictor of relapse.

Nicotine and Stimulant Addiction

A randomized controlled trial found that the GLP-1 medication exenatide, combined with a nicotine patch, helped patients quit smoking at higher rates than the patch alone. Research on cocaine use has shown GLP-1 medications can reduce use by approximately 20% to 26%.

Summary of Key Research Findings

Substance	Finding	Source
Alcohol	50–56% lower risk of AUD incidence/relapse vs. other anti-obesity meds	Søndergaard et al., Nature Communications, 2024
Alcohol	Significant reduction in cravings and consumption in 9-week RCT	Sharma et al., JAMA Psychiatry, 2025
Opioids	40% reduction in opioid cravings over 3 weeks	Stanford Medicine, 2025
Cocaine	20–26% reduction in cocaine use	Frontiers in Pharmacology, 2025
Nicotine	Higher quit rates with exenatide + nicotine patch vs. patch alone	Clinical Trials, 2024

Explore GLP-1 Addiction Treatment at Carrara

New research shows GLP-1 agonists reduce cravings at the neurological level. See how Carrara integrates this into a full recovery program.

Important Notice

FDA Status and Off-Label Use

GLP-1 receptor agonists are FDA-approved for the treatment of type 2 diabetes and obesity. They are not yet FDA-approved for the treatment of substance use disorders. Their use in addiction treatment is considered off-label.

Off-label prescribing is a common, well-established medical practice. At Carrara, all GLP-1 prescriptions for addiction support are made under careful medical supervision, with informed consent, lab monitoring, and integration into a comprehensive treatment plan. Multiple large-scale clinical trials are currently underway, and experts widely expect the evidence base to continue strengthening.

How Carrara Integrates GLP-1 Into Addiction Treatment

“At Carrara, we believe GLP-1 medications may represent one of the most important breakthroughs in addiction medicine in decades — not simply because they can reduce appetite, but because many patients report a meaningful reduction in cravings, compulsive reward-seeking, and the constant ‘mental noise’ surrounding alcohol, food, and other substances.”

“That said, we do not view GLP-1s as a standalone cure. At Carrara, they are integrated into a broader recovery and resilience model that includes exercise, metabolic optimization, behavioral treatment, nutrition, sleep, nervous system regulation, and long-term rebuilding of both physical and mental health.”

Dr. Kenneth Spielvogel, MD, Senior Medical Officer, Carrara Treatment

Stage 1: Stabilization (Weeks 0–4)

The first priority is safe, comfortable detoxification and medical stabilization. Our medical team addresses the acute physiological damage of substance use — restoring liver function, regulating sleep and circadian rhythm, and calming the nervous system. During this phase, we introduce targeted nutraceuticals: NAC for glutathione replenishment and glutamate modulation, omega-3 fatty acids for neuronal repair, and magnesium with L-theanine for anxiety and sleep support. Gentle movement and breathwork begin here.

Stage 2: Metabolic Repair (Weeks 2–12)

Once stabilized, we introduce GLP-1 receptor agonist therapy — typically low-dose semaglutide or tirzepatide — as part of a broader metabolic recovery protocol. The goal is twofold: rebalance the brain’s dopamine and insulin signaling pathways, and support the body’s overall metabolic healing. This is also when deep clinical work intensifies — individual psychotherapy, trauma processing, CBT, DBT, and somatic therapy. GLP-1 medication reduces the noise of cravings, creating more cognitive and emotional bandwidth for the therapeutic work that drives lasting change.

Stage 3: Regeneration (Months 3–6)

With neurochemistry stabilizing, we focus on resilience and physical restoration. Clients engage in progressive strength training, cold plunge therapy, infrared sauna sessions, guided breathwork, and advanced nutritional optimization. Additional regenerative protocols may be considered under medical supervision as part of individualized care.

Stage 4: Longevity and Thriving (Beyond 6 Months)

Recovery at Carrara is not about returning to baseline — it is about exceeding it. In this phase, we optimize hormonal health, cardiovascular function, and cognitive performance. Personalized maintenance protocols for nutrition, supplementation, and somatic therapies ensure that sobriety becomes the foundation for a life of vitality, purpose, and connection.

Break the Craving Cycle — Ask About GLP-1

Carrara is among the first luxury treatment centers to offer GLP-1 therapy as part of an integrated addiction recovery protocol.

Call (888) 383-5207

Who Is GLP-1 Addiction Treatment Right For?

GLP-1 therapy at Carrara may be appropriate for individuals who:

Struggle with intense, persistent cravings for alcohol, opioids, stimulants, or nicotine
Have relapsed despite previous treatment and traditional medication-assisted therapy
Experience co-occurring metabolic issues such as weight gain, insulin resistance, or hormonal imbalance
Are seeking an integrative, medically sophisticated approach to recovery
Value privacy, personalized care, and a luxury treatment environment

GLP-1 therapy is not appropriate for everyone. Candidacy is determined through comprehensive medical evaluation, including lab work, metabolic assessment, and psychiatric screening. Our medical team considers each client’s complete clinical picture before recommending this or any medication.

Why Carrara for GLP-1 Addiction Treatment

Other treatment centers may offer GLP-1 medications. What they cannot offer is the depth of integration and clinical precision that defines Carrara:

Medical Leadership	Dr. Kenneth Spielvogel, MD, Senior Medical Officer, brings deep expertise in metabolic medicine and addiction pharmacology. Every protocol is physician-designed and individually calibrated.
Personalized Clinical Depth	With an exceptionally low client-to-therapist ratio and clinicians with over 20,000 hours of experience, clients receive the sustained individual attention that accelerates insight, builds accountability, and reduces relapse risk.
Holistic Integration	GLP-1 therapy is never standalone. It is woven into a comprehensive protocol that includes psychotherapy, trauma work, nutritional restoration, fitness, breathwork, and community — addressing the full spectrum of what drives addictive behavior.
Absolute Discretion	Whether you are a business leader, public figure, or high-net-worth individual, your privacy is protected at every level. Carrara’s intimate scale and private residential settings ensure complete discretion.

Frequently Asked Questions About GLP-1 and Addiction

Is Ozempic FDA-approved for addiction treatment?

No. GLP-1 medications like Ozempic (semaglutide) are FDA-approved for type 2 diabetes and obesity. Their use in addiction treatment is off-label, supported by a rapidly growing body of clinical evidence. At Carrara, off-label GLP-1 use is supervised by our medical team with full informed consent.

How quickly do GLP-1 medications reduce cravings?

Many patients report noticeable craving reduction within the first two to four weeks, though individual responses vary. In the JAMA Psychiatry trial, significant effects on alcohol cravings and consumption were observed by nine weeks. At Carrara, we monitor response closely and adjust dosing as needed.

Can GLP-1 medications replace traditional addiction treatment?

No — and they should not. GLP-1 medications address the neurochemical dimension of cravings, but addiction involves emotional, psychological, relational, and often spiritual elements. At Carrara, GLP-1 is one component of a comprehensive, multi-modal treatment program that includes therapy, trauma work, lifestyle medicine, and ongoing support.

What are the side effects of GLP-1 medications?

The most common side effects are gastrointestinal: nausea, reduced appetite, and occasional digestive discomfort. These are typically mild and diminish as the body adjusts. Our medical team starts with low doses and titrates gradually to minimize side effects. Serious side effects are rare but are monitored through regular lab work and clinical assessment.

Does insurance cover GLP-1 for addiction treatment?

Insurance coverage for off-label GLP-1 use varies. Because Carrara is a private-pay, ultra-luxury treatment program, our team works directly with clients to ensure access to all recommended medications as part of their comprehensive treatment plan. Contact our admissions team for details.

Take the First Step

Addiction rewires the brain. GLP-1 medications offer a way to begin rewiring it back — reducing the relentless pull of cravings so you can do the deeper work of healing.

At Carrara Treatment Wellness & Spa, we bring together the most advanced pharmacological tools, world-class clinical expertise, and an environment of extraordinary comfort and care. Because you deserve more than sobriety. You deserve to thrive.

Get a Free GLP-1 Assessment

Our clinical team will evaluate whether GLP-1 therapy is the right fit for your recovery journey

Confidential | Available 24/7 | Malibu Beach House & Hollywood Hills

GLP-1 Therapy and Methamphetamine Recovery: What Early Research Suggests

Sharma AN, Ligade SS, Sharma JN, et al. GLP-1 receptor agonists and alcohol use disorder: a systematic review and emerging therapeutic implications. JAMA Psychiatry. 2025.
Søndergaard F, Thomsen M, et al. Association of GLP-1 receptor agonist use with risk of substance use and alcohol-related events. Nature Communications. 2024.
Vallöf D, Maccioni P, Colombo G, et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addiction Biology. 2016;21(2):422–437.
Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Molecular Psychiatry. 2021;26(1):218–233.
Hernandez NS, Schmidt HD. Central GLP-1 receptors: novel molecular targets for cocaine use disorder. Physiology & Behavior. 2019;206:93–105.
Jerlhag E. The gut-brain axis and its role in controlling eating behaviors, metabolism, and addiction. Frontiers in Neuroscience. 2019;13:898.
Simmons SJ, Bhatt DL, et al. GLP-1 receptor agonists in substance use disorders: a review of emerging evidence. Frontiers in Pharmacology. 2024.